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httpcense.Abstract Latent tuberculous infection (LTBI) lacks a solid gold standard in its diagnosis and
many clinicians rely upon tuberculin testing, however there has been an increasing interest in
depending on Interferon Gamma Release Assays especially Quantiferon-Gold (QFT-G). Since
chronic renal failure (CRF) poses an important health problem in Egypt and taking into
consideration the immuno compromisation caused by this condition, LTBI detection emerged as
an important health concern in those patients. In this study, the aim was to ﬁnd which tool was
better in the detection of LTBI in CRF patients. Forty patients with chronic renal failure and on
hemodialysis, with exclusion of active tuberculosis and other immuno compromisation conditions
were tested for LTBI by tuberculin skin test (TST) and QFT-G. 25% of the tested showed LTBI. It
was found that although both tests gave comparable results, yet there was a discrepancy between
both. TST+/QFT+ group was 10%, TST+/QFT group was 5%, TST/QFT+ was 10%
and TST/QFT group was 75%.
Conclusion: In Chronic renal failure and probably any immuno compromisation setting, it would
be better to perform both tuberculin and Quantiferon tests to detect latent tuberculous infection.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.17766220.
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Tuberculosis (TB) was always considered a communicable
infectious disease that had been known for centuries. The
causative bacilli were ﬁrst identiﬁed by Robert Koch in the
nineteenth century [1].
Tuberculosis remains an important public health problem
in Egypt. Egypt is ranked among the mid-level incidence coun-
tries [2]. Moreover, the reported prevalence of chronic renal
failure is 225 pmp in Egypt [3].is. Production and hosting by Elsevier B.V.
0.005
Table 3 Association between laboratory investigations and
tuberculin test results in patient group.
Tuberculin Positive Negative P-value
Laboratory test (n= 6) (n= 34)
Creatinine (Mean ± SD) 8.7 ± 2.6 11.2 ± 2.3 0.023*
BUN (Mean ± SD) 56 ± 16.7 65.9 ± 14.5 0.139
ESR 1 (Mean ± SD) 92 ± 12.8 74.9 ± 29 0.166
ESR 2 (Mean ± SD) 118.3 ± 18.1 102.1 ± 28 0.182
* Signiﬁcant at P 6 0.05.
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losis are asymptomatic, sometimes called latent TB infection
(LTBI), with only a 10% lifetime chance that a latent infection
will progress to TB disease [4]. Normal healthy individuals
with LTBI have an annual risk of 0.1% (1 per 1000) of devel-
oping active TB. However for patients on hemodialysis, the
annual risk of disease, if infected, may be 1–2% [5]. Unfortu-
nately until now there is no full proof gold standard in diagno-
sis of LTBI, however many clinicians rely upon tuberculin
testing [6].
CRF is associated with profound immune deﬁcits; involv-
ing both the humoral and cellular arms; that predispose to
infections [7]. Many studies, have conﬁrmed an increased risk
of TB in patients with chronic renal failure and on dialysis in
comparison to the general population, varying from 6.9 up to
52.5-fold [8,9].
Aim of study
This study aimed at the evaluation of QFT in the diagnosis of
LTBI in CRF patients under hemodialysis.
Methods
The study included 60 adults; 40 of them (patient group) are
patients with end-stage renal disease on regular hemodialysis
in the National Institute of Urology and Nephrology in
EL-Matareyya, Cairo.
All patients with active tuberculosis or other immunosup-
pressing diseases such as Diabetes Mellitus and AIDS, with
liver disease, under corticosteroid treatment for a long period,
with immunologic disorders and with hematological disease
were excluded.
All were subjected to thorough history taking, full clinical
examination, tuberculin skin testing, chest X-ray, sputum
analysis for AFB for 3 successive days, serum levels of BUN
and Creatinine, ESR and Quantiferon TB-Gold (QFT-G)
In-Tube assay.
All the obtained data were collected and statistically
analyzed.Table 1 Association between laboratory investigations and
Quantiferon test results in patient group.
Quantiferon Positive Negative P-value
Laboratory test (n= 8) (n= 32)
Creatinine (Mean ± SD) 9.9 ± 2.9 11.1 ± 2.4 0.247
BUN (Mean ± SD) 59.8 ± 13.7 65.6 ± 15.4 0.331
ESR 1 (Mean ± SD) 78.1 ± 33.2 77.3 ± 26.9 0.938
ESR 2 (Mean ± SD) 99.1 ± 33.9 105.9 ± 25.7 0.533
Table 2 Association between duration of hemodialysis and Quanti
Quantiferon P
Duration (n
Duration of hemodialysis in years (Mean ± SD) 2Results
Tables 1–6.
Discussion
The study at hand aimed at the evaluation of QFT in the diag-
nosis of LTBI in CRF patients undergoing hemodialysis.
Firstly, Quantiferon results were not affected by creatinine,
BUN, ESR, or duration of hemodialysis as shown in Tables
1 and 2. There was no statistically signiﬁcant correlation
between Quantiferon test results in CRF patients and creati-
nine (P-value 0.247), BUN (P-value 0.331), ESR (P-value
0.938 for 1st hour and 0.533 for 2nd hour) levels, or duration
of hemodialysis (P-value 0.056). This was compatible with a
study that revealed that INF-gamma secretion was
independent of the duration of HD treatment [10]. It should
be mentioned, however, that another study found a signiﬁcant
increase of indeterminate QFT results with an increased HD
duration [11].
Secondly, TST results were also not affected by BUN or
ESR as shown in Table 3 with no statistically signiﬁcant
association between TST results in CRF patients and BUN
(P-value 0.139) or ESR (P-value 0.166 for 1st hour and
0.182 for 2nd hour) levels. But results were signiﬁcantly af-
fected by creatinine level and duration of hemodialysis as their
increase gave a negative TST result. TST negative cases
showed a statistically signiﬁcantly higher creatinine level
(P-value 0.023) and mean duration of hemodialysis (P-value
0.021) than TST positive patients as shown in Tables 3 and 4.
This was different from the study which showed no signif-
icant correlation between hemodialysis duration and the TST
reactivity [12]. However, Ates and coworkers found that there
were no associations among the results of TST and QTF-GIT
and duration of hemodialysis of the patients [13]. While Shan-
kar et al. found that values of nutritional status markers
(hemoglobin, albumin and creatinine) were signiﬁcantly higher
among the tuberculin-reactor ESRD patients [14].
There was a statistically signiﬁcant association between
QFT and TST results in the patient group (P-value 0.002) as
mentioned in Table 5. So it might be concluded that Table 5feron test results in patient group.
ositive Negative P-value
= 8) (n= 32)
.1 ± 1 4.3 ± 3 0.056
Table 5 Association between tuberculin and Quantiferon test
results in patient group.
Quantiferon Positive Negative P-value
Tuberculin (n= 8) (n= 32)
TST (Frequency, %)
Positive 4 50 2 6.3 0.002*
Negative 4 50 30 93.8
* Signiﬁcant at P 6 0.05.
Table 4 Results of the association between duration of hemodialysis and tuberculin test results in patient group.
Tuberculin Positive Negative P-value
Duration (n= 6) (n= 34)
Duration of hemodialysis (Mean ± SD) 1.8 ± 1.2 4.2 ± 2.9 0.021*
* Signiﬁcant at P 6 0.05.
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patients. But this could not be true because though TST and
QFT tests were immunologically based, TST and QFT did
not measure the same components of the immunologic re-
sponse and were not interchangeable [15]. Moreover, Table 6
in the study at hand showed the following:
* 20% of CRF patients were QFT positive, 6 (15%) were
TST positive, 32 (80%) were QFT negative and 34 (85%)
were TST negative.
* Only 4 patients had QFT+/TST+, the rest QFT+ were
TST (4 patients) and the rest of TST+ were QFT (2
patients).
This meant that all patients with a positive result either
QFT or TST were 10/40 (25%) of whom 4/10 (40%) were
QFT+/TST+, 4/10 (40%) were QFT+/TST and 2/10
(20%) were QFT/TST+.
In an immunocompetent population, several studies
demonstrate that the combination of TST positive/QTF nega-
tive results dominated the discordant results and most of these
discordant results were explained by BCG vaccination or non-
tuberculous mycobacterial infection (NTM) (e.g., Mycobacte-
rium avium complex) [16]. These cross-reactions tended to
result in small reactions to PPD (<6 mm), but larger reactions
might occur [17].
The greater rate of positive results reported with TST than
with QFT in persons with and without recognized risks forM.
tuberculosis infection might be explained by either greater spec-
iﬁcity with QFT, greater sensitivity with TST, or both [18].Table 6 Comparison between positivity and negativity in both tub
Test Number of patients
QFT+/TST 4
QFT+/TST 4
QFT/TST 2
All 10
QFT/TST -The rest 30Studies found no association between LTBI and having a
positive TST, but found a strong association between prior
BCG vaccination and having a positive TST. Especially that
QFT was not affected by prior BCG vaccination and less inﬂu-
enced by previous infection with NTM; however, TST was var-
iably affected by these factors [19,20].
In comparison to healthy controls, TST reactivity rates
were lower and anergy rates higher in ESRD patients
[13,14,21–23]. These ﬁndings of false TST negativity might
be due to uremic immunosuppression, particularly in BCG
vaccinated population. Also in vitro assays would be able to
detect the very ﬁrst steps in the immune activation cascade, less
inﬂuenced by the uraemic immune suppression than the TST,
which depended on the integrity of the whole immune activa-
tion cascade resulting in a cutaneous induration in vivo [10].
It was shown that HD patients were still able to produce
IFN-gamma ex vivo upon PPD-stimulation, although they
were TST negative; suggesting an immune dysfunction at a la-
ter stage of the activation cascade resulting in cutaneous an-
ergy [24].
Uremia was found to partly inhibit cellular immunity lead-
ing to false negative skin tests [25]. This ﬁnding was proved by
the ﬁnding of a decreased T-cell response, marked by anergy
rate of 32–40% to the intracutaneously administered antigens
in uremic patients [22,26].
In another study, TB diagnosis tended to be hampered by a
negative TST in uremic patients, which was found in some re-
ports in 40–100% of the cases [27]. The anergy was attributed
to uremia and/or dialysis induced defect in the co-stimulatory
function of antigen-presenting cells and a persistent inﬂamma-
tory state of monocytes [28].
High prevalence of QFT positivity may have several expla-
nations such as endemic area for TB, their frequent hospital
contacts, their old age, and uremic immunological defect.
HD patients might have a higher rate of previous tuberculosis
infection. However, when patients over, equal to and under
65 years of age were compared, there were no signiﬁcant differ-
ences with respect to both TST and QFT positivity [29].
Regarding the TST negative/QTF positive discordant
subjects it might be speculated that TST missed these LTBI
diagnoses because of the high speciﬁcity of QFT for the M.
tuberculosis infection. Although a two-step TST was not
performed and this would have maximized the TST sensitivityerculin tested and Quantiferon tested patients.
% Of all + (patients 10) % Of all (patients 40)
40 10
40 10
20 5
100 25
75
164 E.A. Abdel-Nabi et al.[30,31]. However a booster effect could not be ruled out in this
situation and a boosted reaction on a subsequent TST might
be misinterpreted as a newly acquired infection, compared
with the false negative result from the initial TST [32]. It
should also be mentioned that repeating TST was time con-
suming, subject to variability between different readers, and
did not improve speciﬁcity [19,30,31].
In a recent study the absolute number of peripheral blood
lymphocyte and mitogen-stimulated IFN-c response were
found to be closely associated with antigen-stimulated IFN-c
production in whole blood assay in immunologically unse-
lected TB patients [33].
In the present study the overall concordance between TST
and QFT was 85% in ESRD patients; 10% TST and QFT po-
sitive and 75% TST and QFT negative. A ﬁnding substanti-
ated by other studies [13,34].
T-cell assays identiﬁed signiﬁcantly more patients with
LTBI than did the TST and diagnostic agreement varied across
groups [35]. Although, IGRAs and TST were shown to be sim-
ilar in their diagnostic performance for LTBI with approxi-
mately 10% sensitivity beneﬁt for using TST and an IGRA
in combination with a slightly greater speciﬁcity loss [36].
But IGRAs were regarded by some studies as more accurate
in the diagnosis of LTBI in immunocompetent patients than
TST. [37,38].
Lee and his co-researchers compared QFT, ELISPOT, and
TST in ESRD patients on hemodialysis and demonstrated a
high prevalence of LTBI in this population and that QFT
was the most accurate method for identifying those truly in-
fected with M. tuberculosis, even in BCG-vaccinated individu-
als [39].
Conclusion
In Chronic renal failure patients, it is recommended to perform
tuberculin testing and Quantiferon to have a better chance of
detecting LTBI. This is because each test depends on a differ-
ent immunological pathway. Taking into consideration that
LTBI may bear devastating consequences for those patients,
if it progressed to TB, LTBI must be detected.
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